TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Solasia Pharma KK ( (JP:4597) ) has provided an announcement.
Solasia Pharma K.K. announced a fundraising initiative through the issuance of warrants to Macquarie Bank Limited, aiming to raise JPY 2,049 million. The funds will be used to resume the development of SP-05, a colorectal cancer treatment, after previous clinical trials did not meet primary endpoints. The decision to continue development follows a reanalysis by Isofol Medical AB, the licensor of SP-05, which led to the resumption of clinical trials. This move is expected to enhance Solasia’s position in the oncology market and potentially bring a new treatment option for colorectal cancer.
More about Solasia Pharma KK
Solasia Pharma K.K. is a specialty pharmaceutical company based in Asia, primarily focused on developing treatments for cancer. The company is headquartered in Tokyo, Japan, and is involved in the development of pharmaceuticals and medical devices, with a market focus on oncology.
YTD Price Performance: 18.13%
Average Trading Volume: 271
Technical Sentiment Signal: Hold
Current Market Cap: €55.1M
Learn more about 4597 stock on TipRanks’ Stock Analysis page.